The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 63
Summary
- Conditions
- Cellulite
- Edematous Fibrosclerotic Panniculopathy
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 60 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01518907
- Collaborators
- Not Provided
- Investigators
- Study Director: Veronica Urdaneta, MD MPH Endo Pharmaceuticals
Get Well Soon